OWL Lifesciences is attending today the European Virtual Human Twins (VHT) Initiative meeting in Brussels
The VHT Initiative aims to accelerate the development, validation, and adoption of Virtual Human Twin technologies across healthcare, research, and innovation.
At OWL Lifesciences, we are happy to contribute to this initiative reinforcing our believe that integrating in vitro neurovascular models with in silico digital-twin simulations incorporating complementary patient objective bioanalytics — within a large-scale foundation model — will enable a deeper understanding of human brain physiology and pathology, reduce translational gaps, and drive the development of effective, personalised neurotherapies.
This high-level event brings together EU policymakers, researchers, and industry actors to shape the strategic vision for Virtual Human Twin technologies — a key step toward advancing AI-driven, data-based personalised healthcare across Europe.
